OMHealthcare · Medical DevicesThe 3 Wall Street analysts covering Outset Medical, Inc. hold a median 12-month price target of $7 — +73.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Outset Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (87): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (5): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on OM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +73.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Feb 2026 | BTIG | Maintains | Buy | $17 → $15 |
| 7 Jan 2026 | Stifel | Maintains | Buy | — |
| 16 Dec 2025 | BTIG | Reiterates | Buy | — |
| 11 Nov 2025 | BTIG | Maintains | Buy | — |
| 11 Nov 2025 | RBC Capital | Maintains | Sector Perform | — |
| 11 Nov 2025 | Stifel | Maintains | Buy | — |
| 19 Aug 2025 | RBC Capital | Reiterates | Sector Perform | — |
| 7 Aug 2025 | RBC Capital | Maintains | Sector Perform | — |
| 21 May 2025 | RBC Capital | Maintains | Sector Perform | — |
| 8 May 2025 | RBC Capital | Maintains | Sector Perform | — |
| 7 Jan 2025 | RBC Capital | Reiterates | Sector Perform | — |
| 8 Aug 2024 | RBC Capital | Downgrade | Sector Perform | — |
| 8 Aug 2024 | TD Cowen | Maintains | Buy | — |
| 21 June 2024 | RBC Capital | Upgrade | Outperform | — |
| 8 Apr 2024 | BTIG | Initiates | Buy | — |
| 12 Jan 2024 | RBC Capital | Downgrade | Sector Perform | — |
| 4 Dec 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
| 14 Nov 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
| 13 Oct 2023 | B of A Securities | Downgrade | Underperform | — |
| 13 Oct 2023 | RBC Capital | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
OM appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Outset Medical, Inc. returned −68.1% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 77% of US stocks
Cheaper than 76% of US stocks
Cheaper than 66% of US stocks
Higher than 29% of US stocks
Higher than 37% of US stocks
Higher than 52% of US stocks
Higher than 17% of US stocks
Higher than 9% of US stocks
Higher than 19% of US stocks
Higher than 22% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Outset Medical, Inc. has a market value of $78.8M and an enterprise value of $36.0M.
Revenue in the twelve months to 30 June 2026: $117.8M. The latest quarter grew 0.7% year on year.
Net income over the same four quarters: −$74.3M, a −63.1% net margin.
Diluted earnings per share, trailing twelve months: $−4.09.
Free cash flow in the twelve months to 30 June 2026: −$38.9M.
Trailing P/E: −0.8×; forward P/E: −1.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Outset Medical, Inc. employs 310 people — $380K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Outset Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Outset Medical announced that its management will participate in a fireside chat at the 2026 Stifel Healthcare Conference on November 10, 2026, at 1:20 p.m.
Why it matters — The conference appearance is an upcoming opportunity for Outset management to discuss the company with conference attendees.
Outset Medical announced that it will release its third-quarter 2026 financial results after the close of trading on Wednesday, November 4, 2026.
Why it matters — OM watchers can note the scheduled date for the company’s quarterly results.
Zacks Investment Research reported that Outset Medical (OM) passed its "Fast-Paced Momentum at a Bargain" stock screen, indicating the stock has recently exhibited strong momentum while trading at reasonable prices.
Why it matters — An OM watcher would care because the screen suggests the company's stock combines recent upward momentum with an attractive valuation, which could draw further investor attention.
Outset Medical, Inc. released the transcript of its Q2 2026 earnings call, as published by Seeking Alpha. The transcript covers the company's quarterly financial results and management commentary.
Why it matters — OM watchers would care because the earnings call transcript provides direct insight into the company's latest quarterly performance and management's discussion for the period.
Outset Medical reported second-quarter 2026 revenue of $31.6 million, up 1% year over year and 14% sequentially, citing commercial progress, improving margins, and a new $40 million refresh agreement with HCA Healthcare.
Why it matters — A viewer tracking Outset Medical would note the revenue growth and the new $40 million HCA Healthcare agreement as signs of commercial traction for the dialysis technology company.
The 3 Wall Street analysts covering Outset Medical, Inc. have a median 12-month price target of $7, with estimates ranging from $6 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Outset Medical, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Outset Medical, Inc. 38 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Outset Medical, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (87 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +73.7% from the last close, and Ticker Nerd's factor model ranks Outset Medical, Inc. 38 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Outset Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $10 over the next 12 months.
Outset Medical, Inc. returned -68.1% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Outset Medical, Inc. is a medical technology company focused on dialysis care.
The most recent item we track (GlobeNewsWire, 27 Oct 2026): "Outset Medical to Participate in the 2026 Stifel Healthcare Conference". Outset Medical announced that its management will participate in a fireside chat at the 2026 Stifel Healthcare Conference on November 10, 2026, at 1:20 p.m.
Outset Medical, Inc. is a medical technology company focused on dialysis care. Its core product, the Tablo Hemodialysis System, is designed to simplify hemodialysis by combining integrated water purification, on-demand dialysate production, software, and connectivity in a compact platform. The company also provides related consumables and a data ecosystem that includes tools for healthcare providers, patients, and internal analytics. Outset Medical serves hospitals, dialysis clinics, and home-care settings, supporting dialysis delivery across the continuum of care. The company’s products are positioned to help healthcare providers manage dialysis programs with a more streamlined and technology-enabled workflow. Headquartered in San Jose, California, Outset Medical operates in the renal care and medical equipment markets, where it offers a specialized solution for patients and providers involved in kidney replacement therapy.
CEO Ms. Leslie L. Trigg · 310 employees · United States · https://www.outsetmedical.com
